Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …

Background: Historical outcomes in anaplastic thyroid carcinoma (ATC) are poor, with a
median survival of only 5 months and< 20% of patients surviving 1 year from diagnosis. We …

Introduction Although anaplastic thyroid carcinoma (ATC) is rare, it is one of the most
aggressive human cancers. The optimal multimodal therapy policy of ATC is still debated …

ABSTRACT Background The Korean Society of Thyroid Head and Neck Surgery established
a nationwide multicenter registry of anaplastic thyroid carcinoma (ATC) and evaluated the …

Objective To perform a nationwide population based study in ATC on incidence, treatment
and survival. Design Retrospective cohort study. Methods All patients with primary ATC …

The aim of this study was to investigate the role of multimodality treatment in patients with
anaplastic thyroid carcinoma. From 1992 to 1999, 39 consecutive patients with a …

Anaplastic thyroid carcinoma is one of the most aggressive malignancies, with a poor
prognosis. Although rare, representing only 2% of clinically recognized thyroid cancers, the …

Anaplastic thyroid cancer (ATC) is a rare aggressive tumor arising from the follicular cells of
the thyroid gland (as does well differentiated thyroid cancer, WDTC), but ATC cells do not …

Background: Anaplastic thyroid carcinoma (ATC) is an aggressive rare tumor. We analyzed
our experience for prognosis and the effect of surgery and radiotherapy on patients with …

BACKGROUND AND PURPOSE: Anaplastic thyroid carcinoma (ATC) is a rare, aggressive
malignancy. The potential for pathologic misclassification complicates interpretation of …